Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


STOCKWATCH: Pharma reptiles find new skins but risk auto-cannibalism

This article was originally published in Scrip

Executive Summary

Plato, among other ancient sages, described the ouroboros, a mythical snake which ate its own tail. The ouroboros represents cyclicality, eternal return and re-creation. For the pharmaceutical industry, its own symbolic snake traditionally depicted wound round a staff or goblet, ouroboros means lifecycle management, maximizing the return on investment over a drug lifetime that extends beyond patent expiry. But now, as illustrated by the earnings numbers released in the week beginning 22 July from Roche, Shire, and Biogen Idec, pharma is adopting another reptilian characteristic, easing its existing franchises into a new, larger skin. Achieving the transformation successfully, though, means avoiding product cannibalization.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts